IntravitrealWet AMD 6 mg (0.05 mL) by inj every 4 wk (mthly) for the 1st 3 doses, then administer every 12 wk (3 mth) thereafter. May individualize treatment intervals based on disease activity assessed by visual acuity &/or anatomical parameters. Treatment interval could be as frequent as every 8 wk (2 mth), however, interval between 2 doses should not be <8 wk (2 mth). DME 6 mg (0.05 mL) by inj every 6 wk for the 1st 5 doses, then administer every 12 wk (3 mth) thereafter. Treatment intervals should be based on disease activity as assessed by visual acuity &/or anatomic parameters. Patients w/ disease activity Consider treatment every 8 wk (2 mth).
Endophthalmitis, retinal detachment/vasculitis &/or retinal vascular occlusion. Closely monitor patients who experience intraocular inflammation. Transient increase in IOP w/in 30 min of inj. Monitor both IOP & perfusion of optic nerve head. May experience temporary visual disturbance after inj & should be advised not to drive or use machinery until visual function has sufficiently recovered. Pregnancy. Breastfeeding is not recommended during treatment & for at least 1 mth after the last dose. Use effective contraception during treatment & for at least 1 mth after the last dose in females of reproductive potential. Childn <18 yr.
Sign Out
